The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification
Top Cited Papers
Open Access
- 31 January 2021
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (3), 689-703
- https://doi.org/10.1158/1078-0432.CCR-20-0245
Abstract
Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. Here, we briefly outline the principles underlying cancer vaccine therapy with a focus on novel vaccine platforms and antigens, underscoring the renewed optimism. Numerous strategies have been investigated to overcome immunosuppressive mechanisms of the tumor microenvironment (TME) and counteract tumor escape, including improving antigen selection, refining delivery platforms, and use of combination therapies. Several new cancer vaccine platforms and antigen targets are under development. In an effort to amplify tumor-specific T-cell responses, a heterologous prime-boost antigen delivery strategy is increasingly used for virus-based vaccines. Viruses have also been engineered to express targeted antigens and immunomodulatory molecules simultaneously, to favorably modify the TME. Nanoparticle systems have shown promise as delivery vectors for cancer vaccines in preclinical research. T-win is another platform targeting both tumor cells and the TME, using peptide-based vaccines that engage and activate T cells to target immunoregulatory molecules expressed on immunosuppressive and malignant cells. With the availability of next-generation sequencing, algorithms for neoantigen selection are emerging, and several bioinformatic platforms are available to select therapeutically relevant neoantigen targets for developing personalized therapies. However, more research is needed before the use of neoepitope prediction and personalized immunotherapy becomes commonplace. Taken together, the field of therapeutic cancer vaccines is fast evolving, with the promise of potential synergy with existing immunotherapies for long-term cancer treatment.Funding Information
- IO Biotech ApS
This publication has 93 references indexed in Scilit:
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cellsOncoImmunology, 2013
- Natural CD4+ T-Cell Responses against Indoleamine 2,3-DioxygenasePLOS ONE, 2012
- The determinants of tumour immunogenicityNature Reviews Cancer, 2012
- The Present and Future of Peptide Vaccines for CancerThe Cancer Journal, 2011
- Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulatorsBlood, 2011
- A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic AdenocarcinomaAnnals of Surgery, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Cellular Vaccine ApproachesThe Cancer Journal, 2010
- Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancerCancer, 2008
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune ActivationClinical Cancer Research, 2008